[1] Wang HY.Investigation and analysis of the safety content of some Chinese patent medicine instructions[J]. Chinese Journal of Experim-ental Traditional Medical Formulae(中国实验方剂学杂志), 2010, 16(8): 219-222. [2] Yang HJ, LI G.Competitiveness report on science and technology of big brand traditional chinese medicine(2019 Edition)(中药大品种科技竞争力报告)(2019版)[M]. Beijing: People’s Medical Publishing House Co, Ltd, 2020: 23, 51, 86-88. [3] Wang YY, Yang HJ.Cultivation strategy and path analysis on big brand Chinese medicine for small and medium-sized enterprises[J]. China Journal of Chinese Mareria Medica(中国中药杂志), 2014, 39(5): 755-758. [4] Zhang XM, Lin ZJ, Zhou WL, et al.View and suggestions on improving the contraindications of the leaflets of chinese patent drugs[J]. Chin J Pharmacoepidemiol(药物流行病学杂志), 2017, 26(9): 634-637. [5] National Medical Products Administration. Guidelines for writing prescriptions for Chinese and natural medicines[S]. 2006. [6] National Medical Products Administration. Detailed rules for the specification of non-prescription Chinese patent medicines[S]. 2006. [7] Liu X, Zhang B, Wang HN, et al.View and suggestions on improving the‘precaution’section of the leaflets of Chinese Patent Drug[J]. Chin J Pharmacoepidemiol(药物流行病学杂志), 2018, 27(1): 45-49. [8] Zheng R, Zhong CM, Guan MK, et al.Evaluation study on safety information of instructions for exclusive varieties of Chinese materia medica[J]. World Chineses Medicine(世界中医药), 2019, 14(10): 2578-2581. [9] Zhou WL, Lin ZJ, Zhang B, et al.View and suggestions on Improving the adverse reactions of the leaflets of chinese patent drug[J]. Chin J Pharmacoepidemiol(药物流行病学杂志), 2017, 26(11): 774-777. [10] Zhao HQ, Zong Y, Zhen JC.Revision of drug package insert and related risk management measures in China[J]. China Pharmacy(中国药房), 2010, 21(41): 3863-3864. [11] Zhang B, Lin ZJ, Zhang XM, et al.Status and improving suggestions of the leaflets of domestic Chinese patent drugs[J]. Chin J Pharmacoepidemiol(药物流行病学杂志), 2017, 26(8): 561-564. [12] Yu Y, Wang H, Liu HL, et al.Analysis and consideration on risk of sodium aescinate for injection[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(2): 174-177. [13] Zhou X, Xiao H, Wang YP, et al.Quality assessment and improvement suggestions for instruction content of non-injectable Chinese patent medicines[J]. Chinese Journal of Information on TCM(中国中医药信息杂志), 2021, 28(4): 1-5. [14] Zheng R, Chen SQ, Shang HC.The safety evaluation method of Herb-Drug combination: manifestation-target alliance[J]. World Science and Technology/Modernization of Traditional Chinese Medicine and Materia Medica(世界科学技术-中医药现代化), 2018, 20(10): 1734-1738. [15] Hu JY, Zhang XY, Jiang Y, et al.Developing status of clinical research in China and the existing problems, strategies and practices of clinical research of taditional chinese medicine[J]. World Science and Technology/Modernization of Traditional Chinese Medicine and Materia Medica(世界科学技术-中医药现代化), 2018, 20(8): 1417-1421. [16] Mortality DC, Classen MM, Stanley L, et al.Adverse drug events in hospitalized patients:excess length of stay, extra costs, and attributable mortality[J]. JAMA, 1997, 277(4): 301-306. [17] Rothman KJ, Lanes S, Sacks ST.The reporting odds-ratio and its advantages over the proportional reporting ratio[J]. Pharmacoepidemiol Drug Saf, 2004, 13(8): 519-523. [18] Bate A.Bayesian confidence propagation neural network[J]. Drug Saf, 2007, 30(7): 623-625. [19] Fan XH, Zhao XP, Jin Y, et al.Network toxicology and its application to traditional Chinese medicine[J]. China Journal of Chinese Mareria Medica(中国中药杂志), 2011, 36(21): 2920-2922. [20] Hao JX, Gao ZS, Gao H.et al.Cardiotoxicity of aconiti kusnezoffii radix based on network toxicology[J/OL]. Chinese Journal of Experimental Traditional Medical Formulae(中国实验方剂学杂志), 2019, 25(19): 161-169. [21] Gao H, Jia DS, Hao JX, et al.Toxicology of asari radix et rhizoma based on network analysis[J]. Chinese Journal of Experimental Traditional Medical Formulae(中国实验方剂学杂志), 2019, 25(10): 180-187. [22] Sun SG, Sun R.Study on the correlation between drug utilization index and drug information leafl ets of six traditional Chinese medicine injections: From the new view of defined daily dose/concentration[J]. China Journal of Traditional Chinese Medicine and Pharmacy(中华中医药杂志), 2016, 31(9): 3497-3501. [23] Sun SG.Establishment of reevaluation system of clinical rationality and safety of the traditional Chinese medicine injections[J]. China Journal of Traditional Chinese Medicine and Pharmacy(中华中医药杂志), 2017, 32(4): 1411-1414. [24] Zhang CY. Standardizing the instructions of proprietary Chinese medicines is conducive to the long-term development of Chinese medicines [EB/OL].(2018-02-07)[2019-08-01]. http://nespaper.jcrb.com/2018/20180207/20180207_005/20180207_005_2.htm. |